Gr. Sarantis: The H1 Dip Is a Cost-Timing Problem, and the Q4 Margin Decides It

When Gr. Sarantis released its first-half 2026 results on September 8, the headline numbers looked almost boring. Sales rose 1.3% to €308.3 million; underlying EBITDA rose a rounding-error 0.4% to €48.5 million. Boring numbers rarely move a stock. But the shares fell about 3–4% on the day, and the reason was not in those two lines. Buried in the report was a change of behavior: management stopped restating the specific full-year targets it had set in March — the €620 million of sales, the €97 million of EBITDA, the 15.6% margin. A company that has spent two years telling investors exactly where it is going quietly stopped. That is what this quarter is actually about.

To read the report, you have to separate what softened from what did not. Profit did weaken: reported net profit fell 7.9% to €26.9 million, and underlying net profit fell 5.1% to €27.7 million. But the cause, as management laid out on the earnings call, is a cost shock that landed before the company had time to raise prices to offset it. That distinction — costs already in, pricing not yet out — is the entire investment question for 2026.

The plan they stopped printing

In March, on the back of a strong 2025, Sarantis gave specific 2026 targets: sales of €620 million (up 3.4%), EBITDA of €97 million (up 9%), an EBITDA margin of 15.6%, and free cash flow of €63 million. Those numbers were the deal — a consumer-goods compounder promising further margin expansion on top of a year when EBITDA jumped 9.1% to €89.0 million and net profit rose 15.3% to €53.1 million.

In the H1 filing, the outlook section instead carries softer language: the Group "remains optimistic" and is "focused on... safeguarding profitability margins," without reprinting the €97 million or the 15.6%. On the call, CEO Ioannis Bouras was plainer. The environment is "very volatile," he said, with "a lot of uncertainties," so the company "cannot commit to a specific number."

That is a real downgrade in certainty from a management team that has just beaten its plan. It does not mean the plan is dead — management still expects second-half sales growth to accelerate above the 1.3% it printed in the first half — but it means the number you are now underwriting is "will they get back to roughly 15.6%," not "they will."

Why this is timing, not damage

The call explains the wobble. The Middle East disruption pushed up the cost of raw materials, energy, and transportation, and those costs hit in the first half. Consumers were downtrading in a few markets — Romania's sales fell about 5% and Ukraine posted a small loss. A U.S. export phasing issue, a timing of customer stockpiles rather than lost demand, dragged the suncare line, though management says it normalizes in the second half.

The critical detail is the sequencing. Management told investors that pricing increases become "largely effective" only in Q4, and that Q3 is expected to be the weakest quarter for margins. The costs are front-loaded; the response is back-loaded. That is a timing gap, not a broken model — and the fact that gross margin actually held steady at 38.6% suggests the product mix and the in-house regranulation cost cuts are still doing their job.

The proof that this is a pause rather than a structural break sits in the balance sheet and in 2025's cash machine. Sarantis generated €79.5 million of free cash flow last year — more than its €53.1 million of net profit — and used it to move from a small net-debt position into net cash of €23.5 million by year-end. The first-half dividend (the FY2025 payout of €25.0 million, or €0.392 a share, up 25% on the prior year and a 47.1% payout of profit) left room to keep growing it. Net debt is a modest €29.6 million at June 30 — higher only because the company paid a bigger dividend and leaned on working capital — and management said it had already come down toward €19 million and wants to be net cash again by year-end. It also kept buying back its own shares (about 520,000 of them in H1 at an average of €14.57) and holds a €120 million committed, undrawn facility for acquisitions, with management saying the process is "becoming more concrete" in the Eastern European markets where it already operates.

The number that decides it

At roughly €13–14 a share — near the low end of its range, a market value in the low-to-mid €800 millions — Sarantis trades at around 16 times its 2025 earnings. That is not a discount. The honest read is a quality compounder whose multiple has de-rated off its recent highs because the certainty on 2026 got pulled, cushioned by a business that converts profit into cash better than its headline profit suggests.

The opportunity and the risk sit on the same number: the second-half EBITDA margin. If Q4 pricing does what management says it will and the margin claws back toward 15.6%, the €97 million EBITDA plan holds, and a mid-teens multiple looks reasonable for a company with minimal leverage, a dividend that just rose 25%, active buybacks, and real M&A optionality. The dip is the entry. If the cost shock proves durable instead — sustained Middle East disruption, EU–U.S. tariff changes, or deeper consumer downtrading — then 15.6% was always too optimistic, the "flat" underlying EBITDA turns into a decline, and a 16x multiple on shrinking earnings stops looking like a cushion and starts looking like full price for a stalled story.

That is the whole test, and it resolves in the 9-month trading update in late October. The business is intact and well capitalized; what is in question is whether the margin recovery arrives on schedule. Watch the Q3/Q4 EBITDA margin. If it is inflecting back up, this is a compounder you can hold or add. If it is still sliding, the guidance pull was the first warning, not the last.